Making Our COVID Survivors Whole Again By Solving Yet Another Desperate Shortage - Seite 2

MIFTEC’s patented fusion medical isotope generators will solve a number of problems:

1. MIFTEC’s process is fueled by a safe renewable source, namely: seawater. Current production methods are fission-based accelerators or reactors that require enriched uranium to operate, which is costly, must be stored safely, and subject to nuclear weapons proliferation.
2. Production costs are up to 50% less than all other current manufacturing processes.   
3. Small footprint means it can fit into most hospitals, clinics, and labs, resulting in local production, eliminating transportation and importation costs, and greatly reducing the material lost due to half-life decay.  
4. No production limits:  US Nuclear can build MIFTEC’s medical isotope generators in a fraction of the time and cost it takes to build nuclear reactors or accelerators, and production can continue until demand is met.  

Preparations are underway to build the MIFTEC Z-Pinch Fusion Medical Isotope Generators.  Tests conducted by MIFTI at the University of Reno National Terawatt Facility in 2018 using a 1 MegaAmp machine produced a neutron flux in excess of 1010, which demonstrated their device will work as designed. Next, a test at L3 Harris’s 4 MegaAmp machine is scheduled for later this year. The US Air Force MACH-2 simulation code predicts this test will easily produce neutron flux in excess of 1012, or 1 trillion neutrons per pulse: the amount required for commercial production of radioisotopes. MIFTI and MIFTEC have already drawn up plans for a 10 MegaAmp machine, which is designed to provide significant net energy gain for production not only of medical isotopes but also towards electric power generation. US Nuclear is the exclusive manufacturer of MIFTEC’s medical isotope generators in North America and Asia.  

Safe Harbor Act

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov, or the company’s website at www.usnuclearcorp.com 

CONTACT:
US Nuclear Corp. (OTC: UCLE)
Robert I. Goldstein, President, CEO, and Chairman 
Rachel Boulds, Chief Financial Officer
[phone]
Email: [e-mail]